NAMSA, a global leader in medical device testing and regulatory consulting, has finalized the acquisition of Labcorp’s Early Development medical device testing business, marking a major step in its mission to accelerate innovation for MedTech manufacturers worldwide.

 

The deal brings Labcorp’s U.S. portfolio—including biocompatibility, microbiological, and analytical testing, as well as preclinical research—under NAMSA’s roof. The move strengthens NAMSA’s position as a full-service partner for end-to-end medical device development, offering clients expanded expertise and more streamlined solutions across the product lifecycle.

 

“This acquisition is a perfect fit for NAMSA—we serve 3,000+ MedTech companies globally in these specific areas of testing and preclinical research,” said Brian Smith, CEO of NAMSA. “I am confident we will be able to provide Labcorp's medical device clients with a smooth transition combined with the same high level of expertise and customer service current NAMSA clients have come to expect from us.”

 

NAMSA will carry out future testing and preclinical projects for Labcorp’s Early Development clients at its existing facilities in Ohio, Minnesota, Georgia, and California.

 

“The sale of our Early Development medical device testing business to NAMSA allows Labcorp to focus on core areas of preclinical drug development and chemical testing,” said Brian Caveney, EVP and President, Early Development Research Laboratories, Labcorp. “We are pleased NAMSA will continue providing leading expertise to clients in this space and are committed to a seamless transition.”